Characterization of physiochemical and biological properties of spherical protein crystals for sustained release  by Shi, Kai et al.
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 5 8e6 3Available online at wScienceDirect
journal homepage: ht tp: / /ees.elsevier .com/ajps/defaul t .aspOriginal Research Paper
Characterization of physiochemical and biological properties
of spherical protein crystals for sustained releaseKai Shi a,*, Hongshu Bi b, Yanbo Jiang a
aShenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China
b Liaoning Satellite Biotechnology Products Research Institute, No. 51-3, Dongzhan Street, Shenyang 110044, Chinaa r t i c l e i n f o
Article history:
Received 2 January 2013
Received in revised form
24 January 2013
Accepted 27 January 2013
Keywords:
Protein
Spherical crystal
Characterization
Sustained release* Corresponding author. Tel.: þ86 24 23986353
E-mail address: ashikai@163.com (K. Shi).
Peer review under responsibility of Shenyan
Production and hosting by El
1818-0876/$ e see front matter ª 2013 Sheny
http://dx.doi.org/10.1016/j.ajps.2013.07.007a b s t r a c t
This study presents an exploration on extending the action of therapeutic proteins by
crystallization strategy without new molecular entities generation. Recombinant human
interferon a-2b (rhIFN), a model protein drug in this case, was crystallized using a hanging
drop vapor diffusion method. A novel chelating technique with metal ions was employed
to promote crystals formation. The physico-chemical characterization of the protein
crystals, including morphology, particle size, X-ray diffraction, circular dichroism and
biological potency evaluations were performed. In addition, the in vitro release behavior of
rhIFN from crystal lattice suggested an exciting possibility of protein crystals as a long-
acting formulation. The work described here demonstrates the possibility of spherical
crystals of biomacromolecules for controllable delivery application of therapeutic proteins.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction therapeutic proteins is often limited to the frequent paren-The advent of recombinantmolecular biology in the 1970s and
constant improvements in expression methods in the subse-
quent two decades have led to great availability of bio-
macromolecules, many of which have been proved to be quite
effective in treating cancerous, inflammatory, cardiovascular,
respiratory and infectious diseases [1,2]. Despite of the
promising pharmacological activities, the dosing of these; fax: þ86 24 23986355.
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univteral injection currently due to their low stability and thus
rapid clearance in vivo [3,4]. Therefore, much attention has
been paid to the development of extended release formulation
of therapeutic proteins these years. Among the techniques
used for extending the half life of proteins are PEGylation [5]
fusion protein technology [6] and microcapsulation by biode-
gradable polymers [7], etc. All these techniques either involve
chemicalmodification and redesign of themolecules and thussity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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expensive manufacturing processes and result in relatively
low loadings of the active drug substances.
Protein crystallization technology provides us another
promising approach. Compared to its amorphous or lyophi-
lized forms, therapeutic proteins are aligned in the crystals by
a highly order manner and hence be protected in the lattice
structure during processing, upon storage and drug release [8].
Moreover, protein crystals can also allow sustained release of
the therapeutic agents as carrier-free delivery system, thus
avoiding the labor and cost intensive need of repetitive dosing
[9]. Because of great challenges in combination of protein
crystallization engineering and pharmaceutical science, so far
quite a few therapeutic proteins have been crystallized and
only one product, insulin, that is produced and administered
in crystalline form [10].
This work investigates the potential of using protein crys-
tals for local sustained-release application in light of this new
progress. The structure characterization of the crystals,
including morphology, X-ray diffraction, circular dichroism
(CD) and biological potency evaluations were studied. To
explore the possibility of manipulating the release rate of the
developed formulation, the in vitro dissolution behavior was
also investigated. To the best of our knowledge, this research
provides the first trial to achieve controllable delivery of
therapeutic proteins through their own molecular ordered
self-assembly.2. Materials and methods
2.1. Materials
Recombinant human interferon-a-2b (rhIFN), with a biological
potency of 1.36  108 IU/mg, was provided by Huaxin High
Biotechnology Inc. (Shanghai, China). All other reagents and
chemicals were of analytical grade.
2.2. Preparation of rhIFN spherical crystals
Crystallization of rhIFN was performed using the hanging
drop vapor diffusion method in a 24-well Linbro plate (Lin-
bro, USA) [11]. Briefly, a drop of protein solution (5 ml) was
placed on a siliconised glass cover slide and mixed with
equal volume of aqueous buffered solution containing pre-
cipitant, known as crystallization solution. The cover slide is
then inverted over a reservoir well containing the crystalli-
zation solution (1000 ml) and sealed with vacuum grease. The
plates were left in an isothermal environment allowing the
drop equilibrated against reservoir solution until crystals
occurrence.
2.3. Morphology characterization
The morphology of rhIFN spherical crystals was examined
with scanning electron microscopy (SEM) analysis. All sam-
ples were mounted on aluminum stubs, followed by gold
metallization using an ion sputter coater (Hitachi E101, Tokyo,
Japan) and observed on a Hitachi S-2400N scanning electron
microscope (Tokyo, Japan).2.4. Particle size analysis
The size distribution analysis was performed by counting the
particles of different sizes in a microscope image using a DM-
BA400-B light microscope (Motic, China). The number fre-
quencies of occurrence in each size range were determined by
microscopic image analysis. A mean diameter was calculated
as follows:
dn ¼
X
i
Ni$di=
X
i
Ni
where Ni is the number frequency of particles, and di is the
intermediate values of the ith class size. The polydispersity
index (PDI), as a measure of the width of the particle size
distribution, was calculated as PDI ¼ (d90d10)/d50, where d10,
d50 and d90 represent 10%, 50% and 90% of the cumulative
particle size distribution at the given size.
2.5. X-ray diffraction
X-ray diffractograms (XRD) were determined using a PAN-
alytical X’Pert Pro diffractometer equipped with a PIXcel de-
tector (PANalytical B.V., Almelo, Netherlands). Samples were
placed on zero-background silicon plates and measured at
ambient conditions in reflection mode. A continuous 2q scan
was performedwith the diffraction angle increasing from 5 to
40, with a step size of 0.026 using Cu Ka radiation. The
voltage and current applied were set as 30 mA and 30 kV,
respectively. Data were collected using X’Pert Data Collector
software and processed using X’Pert HighScore Plus (PAN-
alytical B.V.). The XRD patterns of spherical crystals were
verified, comparing to that of bulk drug.
2.6. Circular dichroism
Circular dichroism spectra (CD) were utilized to illustrate the
changes in secondary structure of rhIFN in spherical crystals.
The rhIFN spherical crystals were dissolved in PBS (pH 7.4) and
scanned from 250 to 200 nm at a scanning speed of 5 nm/min
for far-UV CD analysis. All CDmeasurements were conducted
with a CD spectropolarimeter (Bio-Logic MOS 450, France,
Grenoble) equipped with a temperature control device. The
generated ellipticity values were subsequently converted to
molar ellipticities using the equation:
½ql ¼ ql=C$L
where ql is the observed ellipticity at thewavelength l, C is the
decimolar rhIFN concentration and the L is the pathlength in
the decimeters.
2.7. Dissolution in vitro
In vitro rhIFN dissolution from spherical crystals was per-
formed in artificial extracellular fluid (Dulbecco’s phosphate-
buffered saline, without CaCl2 and MgCl2, pH 7.4) at 37 C
with continuous orbital mixing (50 r/min). At appropriate in-
tervals, the entire suspensions were subjected to centrifuga-
tion at 5000 g for 5 min. The resulted pellets were re-
suspended in equal volume of fresh dissolution medium.
The amount of rhIFN dissolved in the supernatant was
Table 1 e Characteristics of spherical crystals with
various molar ratio of zinc to rhIFN.
Crystals A B C D
Zinc/rhIFN (mol/mol) 2 4 8 12
Recovery (%) 71.5 76.2 82.4 87.3
Mean size (mm) 18.9 13.1 11.3 8.6
PDI 0.517 0.506 0.425 0.332
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 5 8e6 360evaluated by HPLC analysis. The cumulative rhIFN percentage
dissolved from the spherical crystals was calculated as the
ratio of the amount of rhIFN dissolved at time (t) to the initial
amount used.
2.8. Cytopathic effect inhibition assay
To determine the biological potency retention of rhIFN in
spherical crystals, a cytopathic effect inhibition assay was
performed. The vesicular stomatitis virus (VSV) was used to
produce cytopathic effect on the human amnion WISH cells.
In briefly, WISH cells (3.5  105 cells/ml) were seeded in a 96-
well microtiter and incubated with 4-fold serial dilutions of
rhIFN samples for 24 h at 37 C. After the virus diluent (100
CCID50) was added, the plates were incubated for 24 h until
the cytopathic effect with 90% cell lysis was evident in the
virus control wells. WISH cell viability was determined by
measuring the absorbance of crystal violet-stained living cells
in an ELISA plate. The relative potency of rhIFNwas expressed
as percentage of dilution multiples difference that shows 50%
protection of VSV-induced WISH cells (ED50) between the
spherical crystals and standard rhIFN samples.3. Results and discussion
3.1. Preparation of rhIFN spherical crystals
In this work, macromolecular crystallization aided by metal
ions as chelate ligand was employed for developing protein
crystals into drug formulation. Crystallization of small mo-
lecular therapeutic substances has been employed asFig. 1 e SEM morphology of rhIFN bulkconventional pharmaceutical technology for decades. The
main advantages include better stability, avoidance of
chemical degradation, and varied dissolution characteristics
which allow better control over bioavailability. These advan-
tages can also be envisioned for therapeutic protein crystals
[12,13]. However, protein crystals have not received as much
attention as small chemicals because of great challenges in
biomacromolecular crystallization, which has been often
called the “bottleneck” in X-ray structural determination
[14,15].
The zinc ion plays an important role in forming rhIFN
crystals. Considering the consistency with buffer ions, zinc
acetate was selected as chelating agent for crystals formation.
With 1.5 M acetate buffer (pH 6.0) and rhIFN concentration of
20mg/ml, the hanging dropwas allowed to equilibrate against
reservoir solution under the temperature of 4 C for 6 days.
Crystal occurrence was observed in all the hanging drops
containing various molar ratio of zinc to rhIFN. As seen in
Table 1, an increase in the concentration of zinc acetate led to
an increase recovery of crystals formed. Through interacting
with glutamic acid residues of rhIFN, a distorted tetrahedral
zinc-coordination sphere is formed between two crystallo-
graphic symmetric units of rhIFN crystals, with each unit
composed of three dimers of rhIFN molecules [16]. It is
therefore the involvement of zinc ion that endows the rhIFN
crystal crystallographic integrity.3.2. Characterization of particle morphology and size
distribution
As shown in Fig. 1(B), the crystal rhIFN were characterized as
monodisperse spherical in shape. The surface looks rough and
particle diameter was in about 10e20 mm. Compared with that
of spherical crystal-like protein aggregates, the bulk proteins
were in amorphous shape (seen in Fig. 1A).
The particle size distributions of rhIFN spherical crystals
with zinc at variousmolar ratioswere shown in Fig. 2. It can be
found that co-crystallization with zinc would result in a
reduction of diameter size, which is indicated by mean size of
18.9 mm, 13.1 mm, 11.3 mm and 8.6 mm at 2.0, 4.0, 8.0 and 12.0 M
ratio of zinc to rhIFN, respectively. This size range is ideal for
syringeability and injectability through a fine gauge needle. Asdrugs (A) and spherical crystals (B).
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Fig. 2 e Size-frequency distribution of spherical crystals at
2 (6), 4 (;), 8 (B) and 12 (C) molar ratio of zinc to rhIFN.
Fig. 4 e Far-UV (A) and near-UV (B) circular dichroism (CD)
of rhIFN before (-- -) and after (d) crystallization.
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with an increase in molar ratio of zinc to rhIFN, indicating the
co-crystallizationwith zincwould lead to spherical aggregates
more densely stack via electrostatic intermolecular interac-
tion and thus shrinking in size [17].3.3. Characterization of protein crystals crystallinity
Fig. 3 shows the powder X-ray diffraction patterns of zinc
acetate, bulk rhIFN and spherical crystals of rhIFN. The
diffraction patterns of bulk rhIFN shown in Fig. 3A were
amorphous lacking crystalline peaks. Whereas for spherical
crystals, there are several detectable sharp crystalline peaks
observed in the range of 20e35 apparently, suggesting that
the spherical crystals have possessed certain orderliness,
which can be characterized as crystallinity (Fig. 3B). The
crystallinity was calculated as 22.8% for spherical crystals
with 12.0 M ratio of zinc to rhIFN. It can be also observed that
the sits of crystalline peaks in zinc acetate are different
completely from that of spherical ordered self-assemblies
(seen in Fig. 3C).2θ
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Fig. 3 e X-ray diffraction patterns of rhIFN bulk drugs (A),
spherical crystals (B) and zinc acetate (C).3.4. Characterization of protein secondary structure
To further assess the secondary structure conformation of the
rhIFN in the aggregates, a far-UV CD spectrum of the crystals
in an aqueous medium was measured and compared with
that of the native rhIFN solution (seen in Fig. 4). The shape of
the CD spectra is typical of a-helix and does not indicate a
considerable presence of b structure. It can be found that in
the far-UV region, there are two major negative maximal
bands at 222 nm and 208 nm resulted from Cotton effects of a-
helix, where the first extremum corresponds to the nep*
transition of the peptide bond, and the second is due to the
pep* transition [18]. Both extrema yield similar information of
the conformation of the protein, however, only the data from
the 222 nm region were evaluated for calculating a-helical
content of the rhIFN in crystals because of a better signal-to-
noise ratio. As shown in Fig. 4, analysis of the spectrum of
rhIFN in bulk drug and spherical crystals yielded an estimate
of the a-helical content of approximately 52.8% and 49.2%,
respectively. The difference is not statically significantTime (h)
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Fig. 5 e In vitro dissolution profiles of rhIFN from spherical
crystals at 2 (C), 4 (B), 8 (;) and 12 (6) molar ratio of zinc to
rhIFN.
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Fig. 6 e The bioactivity retention of bulk (C) and
crystallized (B) rhIFN during in vitro release period.
Statistically significant difference from native rhIFN
(*P< 0.05, **P< 0.001).
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tion of rhIFN was not perturbed after crystallization.3.5. Dissolution in vitro
In vitro dissolution profiles of rhIFN from various spherical
crystals were investigated in artificial tissue fluid (pH 7.4) at
37 C. As shown in Fig. 5, there is a strong dependence of the
dissolution rates on the proportion of zinc co-crystallized. For
these formulations, a higher molar ratio of zinc to rhIFN
resulted in a lower initial burst and release rate. The crystals
with 2 M ratio of zinc to rhIFN yielded an initial burst of 90.6%
in the first 2 h. With an increase of zinc addition, the initial
burst percentage was decreased to 38.5%, 17.3% and 12.9%
with 4, 8 and 12 M ratio, respectively. As suggested in the
previous study, doubling the protamine molar ratio to 24 did
not bring a further reduction in initial burst. Increasing molar
ratio of zinc to rhIFN from 4 to 12 did help to improve the
in vitro dissolution characteristics of spherical crystals, which
was indicated by 12 h, 72 h and 96 h for the overall release
period of protein loaded, respectively.
Compared with that of conventional formulations based
on polymeric embedding, the release behaviors of the spher-
ical ordered self-assemblies strongly depended on their own
structures, rather than the particle size suggested commonly
[19,20]. As explained by Flory [21], this difference is due to the
ordered fraction within the crystals, where the molecules are
more densely packed than in the amorphous phase. On the
other hand, the amorphous regions within the semi-crystals
give the material certain elasticity and impact resistance.3.6. Cytopathic effect inhibition assay
The corresponding changes in biological potency retention of
rhIFN from spherical crystals during in vitro release are shown
in Fig. 6. An obvious lost in cytopathic effect inhibition of
native rhIFN can be found with only sixty percent remained
over the release period. However, there were still significantlevels of rhIFN bioactivity remained in crystals for 72 h when
incubation at 37 C due to their ordered structures as revealed
in X-ray analyses.4. Conclusion
Spherical crystals of rhIFNwith desirable sizes and high yields
were successfully prepared. The X-ray, circular dichroism
analysis and cytopathic inhibition assay have shown the
spherical crystals of rhIFN well kept their structural and
functional integrity. The crystals did good sustained-release
performances in vitro studies, making them potential candi-
dates for local sustained-release application of rhIFN.
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